MSD

Unnatural Products, Inc. Enters Research Collaboration with Merck

Retrieved on: 
Tuesday, January 23, 2024
MSD, Entrepreneurship, Chemistry, Head, Macrocycle, Merck & Co., Antibody, Therapy, UNP, Merck, Nature, Pharmaceutical industry

“This collaboration with Merck leverages macrocycles against one of the most challenging oncology targets and is a testament to the progress we have made in intracellular targeting and the importance of finding new ways to tackle the high-hanging fruit in oncology,” said Cameron Pye, CEO and Co-Founder .

Key Points: 
  • “This collaboration with Merck leverages macrocycles against one of the most challenging oncology targets and is a testament to the progress we have made in intracellular targeting and the importance of finding new ways to tackle the high-hanging fruit in oncology,” said Cameron Pye, CEO and Co-Founder .
  • “Merck continues to leverage our strong medicinal chemistry capabilities to advance our oncology pipeline,” said Rob Garbaccio , vice president and head, discovery chemistry, Merck Research Laboratories.
  • “We look forward to working with the Unnatural Products team to develop candidates towards this challenging oncology target.”
    Nature’s solution to hard targets: Macrocycles
    Macrocycles and cyclic peptides offer an opportunity to radically expand the druggable genome.
  • Naturally derived macrocycles have been used as essential medicines across a variety of indications for decades.

Bionomics Provides a Review of 2023 and of 2024 Plans

Retrieved on: 
Monday, January 22, 2024
MSD, Schizophrenia, BNC210, Deficit spending, Patient, Module (mathematics), PAMS, PTSD, Post-traumatic stress disorder, Sleep, Partnership, Merck & Co., GAD, NAM, Anxiety, Neuropsychiatry, SAD, Alzheimer's disease, Central nervous system, Australian Securities Exchange, FDA, DSM-IV codes, CIAS, Breakthrough therapy, Panic, Merck, Phase, Data analysis, Data, CNS, Social anxiety disorder, Pharmaceutical industry

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.
  • “Bionomics continued its evolution into a U.S.-focused, late-stage clinical company last year.
  • Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market.
  • Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.

R1 RCM Completes Acquisition of Acclara, Providence’s Modular Services Business

Retrieved on: 
Wednesday, January 17, 2024
MSD, BDT, Hand, Centerview Partners, LLP, RCM, Adjustment, Partnership, Kirkland & Ellis, McDermott Will & Emery, Acquisition, J. P. Morgan, Internationalized domain name, Reliability-centered maintenance, Real estate

MURRAY, Utah, Jan. 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has completed its previously announced acquisition of Acclara from Providence, one of the nation's largest health systems. In addition, the Company announced that it expects to release financial results for the fourth quarter and full year ended December 31, 2023, and its 2024 outlook and will host a conference call at 8:00 a.m. ET on Tuesday, February 27, 2024, to discuss the results and business outlook.

Key Points: 
  • ET on Tuesday, February 27, 2024, to discuss the results and business outlook.
  • Upon closing, R1 begins its 10-year partnership with Providence for comprehensive revenue cycle services that leverage the breadth of integrated technology and services capabilities of both R1 and Acclara.
  • Centerview Partners LLC and J.P. Morgan acted as financial advisors to R1, and Perkins Coie LLP, Kirkland & Ellis LLP, and Baker Donelson acted as legal counsel.
  • BDT & MSD Partners acted as financial advisor to Providence, and McDermott Will & Emery and ArentFox Schiff LLP acted as legal counsel.

DEPARTMENT OF THE NAVY AWARDS NOBLIS MSD $93 MILLION CONTRACT

Retrieved on: 
Wednesday, January 17, 2024
MSD, Science, Noblis, Navy, Database, Management

Reston, Va., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Noblis MSD, a Noblis subsidiary and leading provider of science, technology and engineering services to the Department of Defense, today announced that it has been awarded the NAVSEA PMS 339 Fleet Introduction contract valued at more than $93 million.

Key Points: 
  • Reston, Va., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Noblis MSD, a Noblis subsidiary and leading provider of science, technology and engineering services to the Department of Defense, today announced that it has been awarded the NAVSEA PMS 339 Fleet Introduction contract valued at more than $93 million.
  • Under this contract, the Noblis team will continue providing on-site, waterfront-based administrative, logistics, manning and training, commissioning, network administration and database development services at the Navy's Fleet Concentration areas and shipbuilding yards.
  • “The Noblis MSD Fleet Introduction team is an accomplished and experienced technical team,” said Glenn Hickok , president of Noblis MSD.
  • “On day one, they have an acute understanding of the requirements needed to support the customer and its crews.”

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Retrieved on: 
Saturday, January 27, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, Dana–Farber Cancer Institute, Renal cell carcinoma, Death, VEGF, Patient, M1, OS, RCC, Harvard Medical School, ASCO, Survival, DFS, Medicine, Society, NED, Cancer, Nephrectomy, Kidney, Risk, Recurrence, Disease, Safety, Eisai, Merck & Co., CPS, Rated R, MRK, Pharmaceutical industry

At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.

Key Points: 
  • At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.
  • Treatment-related adverse events (TRAEs) occurred in 79.1% of patients (n=386) in the KEYTRUDA arm and 53.0% of patients (n=263) in the placebo arm.
  • Grade 3-4 TRAEs occurred in 18.6% of patients in the KEYTRUDA arm and 1.2% of patients in the placebo arm.
  • Treatment-related adverse events resulting in discontinuation of any treatment occurred in 18.2% of patients in the KEYTRUDA arm and 0.8% of patients in the placebo arm.

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

Retrieved on: 
Friday, January 26, 2024
Biotechnology, FDA, Diabetes, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, MSD, Development, Death, Patient, OS, Carcinoma, Bladder cancer, ASCO, DFS, Society, NCI, Cancer, ClinicalTrials.gov, Risk, PD-L1, Recurrence, Disease, National Cancer Institute, Safety, Merck & Co., Observation, Pembrolizumab, Rated R, Bangladesh Technical Education Board, MRK, Pharmaceutical industry

Median DFS was 29.0 months (95% CI, 21.8-not evaluable [NE]) for KEYTRUDA and 14.0 months (95% CI, 9.7-20.20) for observation, an improvement of 15 months.

Key Points: 
  • Median DFS was 29.0 months (95% CI, 21.8-not evaluable [NE]) for KEYTRUDA and 14.0 months (95% CI, 9.7-20.20) for observation, an improvement of 15 months.
  • AMBASSADOR (A031501)/KEYNOTE-123 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT03244384 ) evaluating KEYTRUDA versus observation for the adjuvant treatment of patients with localized MIUC and locally advanced resectable urothelial carcinoma.
  • 17.4% of patients receiving KEYTRUDA withdrew from the trial without event versus 27.2% from the observation arm.
  • Grade ≥3 adverse events occurred in 48.4% of patients receiving KEYTRUDA versus 31.8% of patients under observation.

Merck Announces Second-Quarter 2024 Dividend

Retrieved on: 
Tuesday, January 23, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, MRK

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the second quarter of 2024.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the second quarter of 2024.
  • Payment will be made on April 5, 2024, to shareholders of record at the close of business on March 15, 2024.

Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1

Retrieved on: 
Friday, January 19, 2024
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, News, MRK, Webcast

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m.
  • During the call, company executives will provide an overview of Merck’s performance for the fourth quarter and outlook for 2024.
  • Investors, journalists and the general public may access a live audio webcast of the call via this weblink .
  • A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will be available at www.merck.com .

National Safety Council to Award Up to $260,000 to Expand Grant Programs to Solve Most Common Workplace Injury

Retrieved on: 
Friday, January 19, 2024
MSD, Musculoskeletal disorder, National Safety Council, Occupational injury, Research, Heart, Carpal tunnel syndrome, Safety, Injury, Partnership, Risk, NSC, Congress, Tendinopathy, Organization, Private sector, Council, AMZN, Liberty Mutual, Logging

WASHINGTON, Jan. 19, 2024 /PRNewswire/ -- Following the debut of the Research to Solutions (R2S) grant and MSD Solutions Pilot Grant in 2023, the National Safety Council is awarding up to an additional $260,000 this year through these pioneering grant programs to help uncover promising new safety solutions to prevent work-related musculoskeletal disorders, or MSDs. As a key initiative of the Council's MSD Solutions Lab, a groundbreaking strategic program established in 2021 with funding from Amazon (NASDAQ: AMZN), a total of up to $535,000 has now been committed in grants to foster innovative, transferable methods to mitigate MSDs – the most common workplace injury – across a range of sectors and workplaces.  

Key Points: 
  • "We are pleased to continue our partnership with NSC on the MSD Solutions Lab," said Sarah Rhoads, Vice President of Global Workplace Health and Safety at Amazon.
  • "The Research to Solutions and MSD Pilot Grant programs will advance research and create scalable MSD mitigation programs that help improve safety for employees on a global scale."
  • The R2S and MSDs Pilot Grant are two of several initiatives supported by the MSD Solutions Lab to achieve its goal of preventing MSDs.
  • To learn more about the grant programs and application requirements, click here .

Davos '24: Bill Gates Joins Belgium in Showcase of Innovation and Global Partnerships

Retrieved on: 
Wednesday, January 17, 2024
MSD, DEME, House, Conscience, Belfius, Society, DNA, Tech, Partnership, Science, Majesty, Global Health, AB InBev, AI, Global Affairs Canada, Petra De Sutter, HSBC, Federation, Interior, Road, AB, Clean technology, International Atomic Energy Agency, Democracy, Annual general meeting, Ackermans & van Haaren, Lace

The Belgium House is an initiative from European Business Summits and a group of leading Belgian companies, with the support of the Belgian federal government, to showcase Belgian technology and innovation.

Key Points: 
  • The Belgium House is an initiative from European Business Summits and a group of leading Belgian companies, with the support of the Belgian federal government, to showcase Belgian technology and innovation.
  • Prime Minister Alexander De Croo is hosting three flagship events at the Belgium House encapsulating Belgium's commitment to drive progress for all by embracing openness , innovation and global partnerships.
  • On Tuesday, Belgium demonstrated its green transition leadership during the "Clean Tech Innovation on the Road to Net Zero" discussion.
  • "Davos is the perfect forum to invite others to join us in uncovering sustainable and innovative solutions for global challenges."